A carregar...
Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors
The Phosphoinositide-3-kinase (PI3K) pathway is often aberrantly activated in Estrogen Receptor positive (ER+) breast cancer and therapies combining PI3K inhibitors and anti-estrogens are under clinical development. Given that many PI3K inhibitors have substantial toxicities with continuous dosing a...
Na minha lista:
| Publicado no: | Clin Cancer Res |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4946572/ https://ncbi.nlm.nih.gov/pubmed/26957555 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0038 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|